Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: January 2011

6 - Measuring quality of life in multiple system atrophy

Related content

Powered by UNSILO


1. SchragA, Ben-ShlomoY, QuinnNP.Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999 Nov 20; 354(9192): 1771–1775.
2. ChrysostomeV, TisonF, YekhlefF, SourgenC, BaldiI, DartiguesJF.Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004 Jul; 23(4): 201–208.
3. VanacoreN, BonifatiV, FabbriniG, ColosimoC, DeMG, MarconiR, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci 2001 Feb; 22(1): 97–99.
4. SchragA, GeserF, Stampfer-KountchevM, SeppiK, SawiresM, KollenspergerM, et al. Health-related quality of life in multiple system atrophy. Mov Disord 2006 Jun; 21(6): 809–815.
5. Benrud-LarsonLM, SandroniP, SchragA, LowPA.Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 2005 Aug; 20(8): 951–957.
6. WenningGK, TisonF, BenSY, DanielSE, QuinnNP.Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997 Mar; 12(2): 133–147.
7. JellingerKA, SeppiK, WenningGK.Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005 Aug; 20(suppl 12):S29–S36.
8. Ben-ShlomoY, WenningGK, TisonF, QuinnNP.Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997 Feb; 48(2): 384–393.
9. KawaiY, SuenagaM, TakedaA, ItoM, WatanabeH, TanakaF, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008 Apr 15; 70(16 Pt 2): 1390–1396.
10. WenningGK, TisonF, SeppiK, SampaioC, DiemA, YekhlefF, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004 Dec; 19(12): 1391–1402.
11. HoehnMM, YahrMD.Parkinsonism: onset, progression and mortality. Neurology 1967 May; 17(5): 427–442.
12. SchwabRS, EnglandAC.Projection technique for evaluating surgery in Parkinson's disease. In: GillinghamFJ, DonaldsonIML, eds. Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969; pp. 152–157.
13. TrouillasP, TakayanagiT, HallettM, CurrierRD, SubramonySH, WesselK, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997 Feb 12; 145(2): 205–211.
14. SuarezGA, Opfer-GehrkingTL, OffordKP, AtkinsonEJ, O’BrienPC, LowPA.The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. Neurology 1999 Feb; 52(3): 523–528.
15. WareJE, Jr., SherbourneCD.The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 Jun; 30(6): 473–483.
16. McHorneyCA, WareJE, Jr., RaczekAE.The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 Mar; 31(3): 247–263.
17. The Euro-Qol Group. EuroQol–a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990 Dec; 16(3): 199–208.
18. BeckAT, WardCH, MendelsonM, MockJ, ErbaughJ.An inventory for measuring depression. Arch Gen Psychiatry 1961 Jun; 4: 561–571.
19. PetoV, JenkinsonC, FitzpatrickR.PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998 May; 245(suppl 1): S10–S14.
20. SchragA, JenkinsonC, SelaiC, MathiasC, QuinnN.Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism Relat Disord 2007 Apr; 13(3): 152–156.
21. MarinusJ, LeentjensAF, VisserM, StiggelboutAM, van HiltenJJ.Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 2002 Nov; 25(6): 318–324.
22. SchragA, SelaiC, MathiasC, LowP, HobartJ, BradyN, et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov Disord 2007 Dec; 22(16): 2332–2338.
23. NunnallyJC, BernsteinIH.Psychometric Theory. 3rd ed. New York: McGraw-Hill, 1994.
24. JuniperEF, GuyattGH, JaeschkeR.How to develop and validate a new health-related quality of life instrument. In: SpilkerB, ed. Quality of Life and Pharmaeconomics in Clinical Trials. Philadelphia, New York: Lippincott-Raven, 1996.
25. MarxRG, BombardierC, Hogg-JohnsonS, WrightJG.Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999 Feb; 52(2): 105–111.
26. StreinerDL, NormanGR.Health measurement scales: a practical guide to their development and use. 2nd ed. Oxford: Oxford University Press, 1995.
27. NagataC, IdoM, ShimizuH, MisaoA, MatsuuraH.Choice of response scale for health measurement: comparison of 4, 5, and 7-point scales and visual analog scale. J Epidemiol 1996 Dec; 6(4): 192–197.
28. GilmanS, LowPA, QuinnN, AlbaneseA, Ben-ShlomoY, FowlerCJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999 Feb 1; 163(1): 94–98.
29. World Health Organization. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 1998 Jun; 46(12): 1569–1585.
30. WareJE, HarrisWJ, GandekB, RogersBW, ReesePR.MAP-R for Windows: multitrait/multi-item analysis program, revised user's guide. Boston: Health Assessment Laboratory, 1997.
31. ZigmondAS, SnaithRP.The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 Jun; 67(6): 361–370.
32. HobartJ, FreemanJ, LampingD, FitzpatrickR, ThompsonA.The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry 2001 Sep; 71(3): 363–370.
33. LikertRA.A technique for the development of attitudes. Arch Psych 1932; 140: 5–55.
34. GeserF, WenningGK, SeppiK, Stampfer-KountchevM, ScherflerC, SawiresM, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006 Feb; 21(2): 179–186.
35. BrazierJE, WaltersSJ, NichollJP, KohlerB.Using the SF-36 and Euroqol on an elderly population. Qual Life Res 1996 Apr; 5(2): 195–204.
36. BrazierJE, HarperR, JonesNM, O’CathainA, ThomasKJ, UsherwoodT, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992 Jul 18; 305(6846): 160–164.
37. SchragA, SelaiC, JahanshahiM, QuinnNP.The EQ-5D–a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000 Jul; 69(1): 67–73.
38. FreemanJA, HobartJC, LangdonDW, ThompsonAJ.Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000 Feb; 68(2): 150–156.
39. HobartJC, WilliamsLS, MoranK, ThompsonAJ.Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke 2002 May; 33(5): 1348–1356.
40. NeudertC, WasnerM, BorasioGD.Patients’ assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001 Oct 15; 191(1–2): 103–109.